BioPharmSignal logoBioPharmSignal

Biotech News

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

Bluejay Diagnostics (BJDX)Bluejay DiagnosticsConference / presentation

New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented. ACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient

Open original release

Related news

BJDXBluejay Diagnostics2026-07-21 10:30 EST

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BDSXBiodesix2025-12-03 13:22 EST

Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

OSUROraSure Technologies, Inc.2025-11-17 12:45 EST

OraSure to Participate in Upcoming Investor Conference

LUCDLucid Diagnostics2026-04-09 12:01 EST

Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference

FLGTFulgent Genetics, Inc.2025-10-20 10:00 EST

Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

BDSXBiodesix2025-10-30 10:17 EST

Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting

INBSIntelligent Bio Solutions2026-06-04 12:30 EST

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

FLGTFulgent Genetics, Inc.2026-05-21 21:03 EST

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

MDXHMDxHealth2026-05-13 20:00 EST

Mdxhealth Reports Q1-2026 Results

View all latest news

Bluejay Diagnostics

Bluejay Diagnostics is a medical diagnostics company focused on rapid testing and blood-based diagnostic tools. Its business is centered on bringing point-of-care information to clinical settings rather than developing therapeutics.

Recent company news

BJDXBluejay Diagnostics2026-07-21 10:30 EST

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 16:19 EST

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 10:30 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

BJDXBluejay Diagnostics2026-05-07 20:01 EST

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Stock data

Close
1.00 USD
Market cap
4.49M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States